245
Participants
Start Date
February 15, 2018
Primary Completion Date
January 8, 2025
Study Completion Date
January 8, 2025
CAB-AXL-ADC
Conditionally active biologic anti-AXL antibody drug conjugate
PD-1 inhibitor
PD-1 inhibitor
Columbia University, New York
Memorial Sloan Kettering, New York
Roswell Park Cancer Institute, Buffalo
The Children's Hospital of Philadelphia, Philadelphia
Abramson Cancer Center at Pennsylvania Hospital, Philadelphia
Children's Research Institute, Washington D.C.
Wake Forest Baptist Health, Winston-Salem
Duke Cancer Institute, Durham
Moffitt Cancer Center, Tampa
Tennessee Oncology, Nashville
Vanderbilt Ingram Cancer Center, Nashville
Norton Cancer Institute, Louisville
Nationwide Children's Hospital, Columbus
The Ohio State University Wexner Medical Center, Columbus
University Hospitals Seidman Cancer Center, Cleveland
The Christ Hospital, Cincinnati
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Northwestern University, Chicago
Washington University School of Medicine - Siteman Cancer Center, St Louis
Mary Crowley Cancer Research, Dallas
MD Anderson Cancer Center, Houston
University of Colorado, Aurora
Sarah Cannon Research Institute at Health One, Denver
University of Utah - Huntsman Cancer Institute, Salt Lake City
The University of Arizona Cancer Center, Tucson
Comprehensive Cancer Center of Nevada, Las Vegas
Children's Hospital Los Angeles, Los Angeles
USC Norris Comprehensive Cancer Center, Los Angeles
Tower Hematology Oncology Medical Group, Los Angeles
Precision NextGen Oncology, Los Angeles
UCSF Medical Center - Cancer Immunotherapy Clinic (CIC), San Francisco
Oregon Health & Science University, Portland
Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Prince of Wales Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
National Cheng Kung University Hospital, Tainan City
Taipei Veterans General Hospital, Taipei
Chang Gung Memorial Hospital, Taoyuan District
Lead Sponsor
BioAtla, Inc.
INDUSTRY